1. Anti-infection
  2. Bacterial

Oritavancin diphosphate (Synonyms: LY333328 diphosphate)

Cat. No.: HY-B1831A Purity: 99.17%
Data Sheet SDS Handling Instructions

Oritavancin diphosphate is a novel semisynthetic glycopeptide antibiotic being developed for the treatment of serious Gram-positive bacterial infections.

For research use only. We do not sell to patients.
Oritavancin diphosphate Chemical Structure

Oritavancin diphosphate Chemical Structure

CAS No. : 192564-14-0

Size Price Stock Quantity
10 mM * 1 mL in DMSO $525 In-stock
2 mg $70 In-stock
5 mg $150 In-stock
10 mg $240 In-stock
50 mg $950 In-stock
100 mg $1650 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Oritavancin diphosphate is a novel semisynthetic glycopeptide antibiotic being developed for the treatment of serious Gram-positive bacterial infections. Target: Antibacterial Oritavancin is a lipoglycopeptide.Oritavancin has completed clinical trials and submitted a new drug application for treatment of skin infections.

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01784536 The Medicines Company Healthy January 2013 Phase 1
NCT02340988 The Medicines Company Healthy April 2015 Phase 1
NCT02452918 The Medicines Company Acute Bacterial Skin and Skin Structure Infection June 2015 Phase 4
NCT03159403 The Medicines Company Gram-Positive Bacterial Infections April 12, 2017
NCT02471690 The Medicines Company Healthy July 2015 Phase 1
NCT02134301 The Medicines Company Gram Positive Bacterial Infections May 2014 Phase 1
NCT02357524 The Medicines Company|Christchurch Clinical Studies Trust Ltd Healthy Volunteers January 2015 Phase 1
NCT01762839 The Medicines Company Healthy January 2013 Phase 1
NCT02470702 The Medicines Company Healthy June 2015 Phase 1
NCT01252719 The Medicines Company Wound Infection|Abscess|Systemic Inflammation|Cellulitis December 2010 Phase 3
NCT01252732 The Medicines Company Wound Infection|Abscess|Systemic Inflammation|Cellulitis December 2010 Phase 3
NCT02925416 The Medicines Company Skin Diseases, Bacterial January 2017 Phase 4
NCT00514527 Targanta Therapeutics Corporation Staphylococcal Skin Infections|Wounds and Injuries|Abscess|Cellulitis|Streptococcal Infections August 2007 Phase 2
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 0.5027 mL 2.5137 mL 5.0274 mL
5 mM 0.1005 mL 0.5027 mL 1.0055 mL
10 mM 0.0503 mL 0.2514 mL 0.5027 mL
References
Molecular Weight

1989.09

Formula

C₈₆H₁₀₃Cl₃N₁₀O₃₄P₂

CAS No.

192564-14-0

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: 14 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Oritavancin diphosphate
Cat. No.:
HY-B1831A
Quantity: